Clinical Trial Update: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TACE combined with camrelizumab and rivoceranib (apatinib) for incurable hepatocellular carcinoma is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Rivoceranib (rivoceranib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING